AstraZeneca Shares Jump Most Since 2020
Pascal Soriot, CEO of AstraZeneca, joins the Bloomberg Intelligence to discuss AstraZeneca earnings, along with regulatory and scientific updates. He spoke with Paul Sweeney and Molly Smith on Bloo...
AstraZeneca CEO talks blowout earnings, global growth, new drugs, and pricing
AstraZeneca shares (AZN) revealed a first-quarter earnings beat on Thursday, posting revenue of $12.68 billion, a 19% year-over-year gain. In addition, the pharmaceutical giant has reiterated its f...
AstraZeneca Gets a Boost From Sales of Its Cancer Drugs
American depositary receipts (ADRs) of AstraZeneca (AZN) traded near their all-time high as the Anglo-Swedish pharmaceutical company had solid first-quarter demand for its cancer drugs.
AstraZeneca tops first-quarter revenue and profit expectations
AstraZeneca CEO Pascal Soriot outlines how the pharma giant's first-quarter results were boosted by demand for its rare blood disorder and oncology drugs.
AstraZeneca is now Britain's top stock- can it move higher?
AstraZeneca PLC (LSE:AZN)'s first-quarter results were thoroughly welcomed by the market. So much so, that its market valuation has surpassed oil major Shell to become Britain's most valuation corp...
AstraZeneca earnings beat expectations as steady drug sales boost revenues
AstraZeneca plc today, on April 25, announced its earnings report for the first quarter of FY24. Total Revenue increased by 19% to $ 12,679 million, driven by an 18% increase in product sales and c...
AstraZeneca overtakes Shell as Britain's most valuable company.
AstraZeneca PLC (LSE:AZN)'s solid rally following Thursday's first-quarter earnings print has made the pharmaceuticals giant Britain's most valuable company, overtaking oil major Shell. AstraZeneca...
AstraZeneca CFO on Earnings, US Inflation Reduction Act, China Market
AstraZeneca Chief Financial Officer Aradhana Sarin discusses first-quarter earnings, implications of the US Inflation Reduction Act and the outlook for the company's commercial business in China. S...
AstraZeneca ticks the boxes in first quarter
Britain's leading pharmaceuticals company AstraZeneca hit the mark in today's first-quarter earnings print. Total revenue increased by 19% at constant exchange rates to $12.7 billion (£10.2 billion...
AstraZeneca beats first-quarter revenue, profit estimates
AstraZeneca reported quarterly revenue and profit above market estimates on Thursday, buoyed by resilient demand for its oncology and rare blood disorder drugs.
Britain's Magnificent 7: Do Rolls-Royce, AstraZeneca and Unilever make the cut?
The Magnificent 7 will be hogging US financial news headlines over the coming weeks. Not to be confused with the Yul Byrnner-starring 60s Western classic, the term refers to the seven premier Big T...
ANGLE shares jump 30% on AstraZeneca tie-up
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) shares jumped 30% following the announcement of a strategic partnership with AstraZeneca PLC (LSE:AZN) that aims to advance cancer drug development by enhancing the...
ANGLE inks AstraZeneca deal to develop ground-breaking cancer assay
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technologies, has partnered with AstraZeneca PLC (LSE:AZN) to enhance cancer drug development by 'leveraging' the former's DNA damag...
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
Related Companies